

- Neutrophils, 515-516, 515f-516f, 824-825  
 clinical disorders of, 515-519  
 normal granulocyte development structure and function of, 515-517
- New daily persistent headache, 998
- New York Heart Association Functional Classification, 26, 27t
- New York Heart Association (NYHA), functional classification of heart failure, 55, 55t
- Nicardipine, in hypertensive emergency, 178, 179t
- Nicotinic acid, 694
- Nifedipine, in acute coronary syndrome, 101
- Night-eating syndrome, obesity and, 675-676
- Night terrors, 974
- Nilotinib, 494
- Nitrates  
 in acute coronary syndrome, 101  
 for angina pectoris, 95  
 for heart failure, 63-64  
 for myocardial infarction, 109  
 phosphodiesterase inhibitors and, 718
- Nitric oxide  
 as coronary vasodilator, 21  
 in sepsis, 848f, 849  
 sexual stimulation and, 716-717, 717f  
 skin and soft tissue infection and, 884
- Nitrofurantoin  
 drug-induced liver injury and, 453  
 pulmonary toxicity of, 231
- Nitroglycerin  
 for acute STEMI, 105  
 for angina pectoris, 95  
 for heart failure, 60  
 in hypertensive emergency, 178, 179t  
 topical, for Raynaud phenomenon, 791
- Nitroprusside  
 in acute severe regurgitation, 80  
 in heart failure, 60  
 in hypertensive emergency, 178, 179t
- Nizatidine, for peptic ulcer disease, 407
- Nodular melanoma, 615
- Nodules, rheumatoid, 772
- Non-hemophilia A or B congenital factor deficiencies, 559-560
- Non-Hodgkin's lymphomas, 522-526  
 classification of, 522t  
 clinical presentation of, 523  
 diagnosis and differential diagnosis of, 523  
 in HIV-infected patients, 940-941  
 in systemic lupus erythematosus, 785-786  
 treatment of, 523-524  
 for aggressive type, 525  
 for high-grade, 526  
 for indolent types, 524-525  
 for mantle cell lymphoma, 525-526
- Non-insulin antidiabetic agents, 665-667, 666t
- Non-insulinoma pancreatogenous hypoglycemia, 672
- Non-ionizing radiation, cancer risk and, 582
- Non-islet cell neoplasms, hypoglycemia and, 672
- Non-pain, 1120
- Non-small cell lung carcinomas, 592  
 treatment for, 596-597
- Non-ST elevation myocardial infarction (NSTEMI), 89  
 acute coronary syndrome and, 98-102
- Non-urate-lowering prophylactic therapy, 802
- Nonalcoholic fatty liver disease (NAFLD), 454-455
- Nonalcoholic steatohepatitis (NASH), chronic hepatitis and, 453
- Nondeclarative memory, 984
- Nonfamilial cardiomyopathy, 141t
- Nonimmunologic host defenses, 822-823
- Noninvasive vascular testing, 53-54
- Nonpenetrating cardiac injuries, 146, 146t
- Nonpharmacologic therapies, in COPD, 214-215
- Nonseminomas, 607-608
- Nonsense mutation, 6
- Nonseptic bursitis, 810-811
- Nonsteroidal anti-inflammatory drugs (NSAIDs)  
 in acute kidney injury, 356  
 in acute pericarditis, 137  
 antiplatelet effects of, 539  
 for bursitis, 811  
 for calcium pyrophosphate dihydrate, 803  
 gastroduodenal mucosal injury induced by, 405  
 for gout, 802  
 and heart failure, 64  
 liver biopsy and, 442  
 for osteoarthritis, 807  
 peptic ulcer disease and, 405-406  
 treatment and prophylaxis of, 409-410, 409t  
 platelet dysfunction caused by, 554, 554t, 556t  
 for reactive arthritis, 779  
 for rheumatoid arthritis, 773  
 for spondyloarthritis, 778-779  
 for tendinitis, 811
- Nontreponemal test, for syphilis, 923
- Nontropical sprue, 383
- Nontyphoidal salmonellosis, 900-901
- Nonulcer dyspepsia, 413
- Norepinephrine, 650
- Normocytic anemias, 507-508  
 treatment of, 508
- Norovirus, diarrhea from, 902
- Nosocomial infective endocarditis, 878
- Nosocomial pneumonia, 255-256
- NSAIDs. *see* Nonsteroidal anti-inflammatory drugs (NSAIDs).
- Nuclear imaging, for renal artery stenosis, 343
- Nucleation, 469-470
- Nucleic acid amplification, 887
- Nucleic acid amplification testing (NAAT), 919
- Nucleosomes, 5, 6f
- 5'-Nucleotidase (5'-NT), 440, 441t
- Nutrient deficiencies, clinical manifestations of, 684.e2t
- Nutrition  
 cancer risk and, 581  
 in older adults, 1111  
 thrombocytopenia associated with, 548-549
- Nutritional assessment, 683-685, 684t, 684.e1t
- Nutritional care, for acute pancreatitis, 430-432
- Nutritional management  
 in type 1 diabetes, 662-663  
 in type 2 diabetes, 667
- Nutritional supplements, heart failure and, 64
- Nutritional support, 685-688, 685t  
 in inflammatory bowel disease, 424
- Nystagmus, 1003, 1010, 1010t
- O**
- Obesity, 252, 675-682  
 assessment of, 677-678  
 in coronary artery disease, 88  
 definition of, 675  
 diagnosis of, 677-678  
 epidemiology of, 675  
 in metabolic syndrome, 664  
 morbid, 675  
 pathology of, 675-676  
 prognosis of, 681  
 risks associated with, 676-677  
 cancer, 581  
 sleep apnea, 245  
 screening of women for, 702t  
 treatment of, 678-681, 678t  
 bariatric surgery in, 680-681, 680f  
 behavior modification in, 679  
 lifestyle modification in, 678-679  
 patient education in, 679  
 pharmacologic options in, 679-681  
 in women, 709
- Obesity-hypoventilation syndrome, 245-246
- Obsessive-compulsive disorder, 988
- Obstructive jaundice, 447
- Obstructive lung diseases, 184, 184f, 207-221  
 classification of, 207f  
 features of, 208t  
 physical examination in, 187  
 testing in  
 flow-volume loops, 201, 202f  
 spirometry, 200, 200.e1f
- Obstructive nephropathy, 332, 332t, 360
- Obstructive shock, 263
- Obstructive sleep apnea (OSA), 971
- Obstructive uropathy, 360
- Occipital lobe epilepsy, 1055
- Occipital lobe seizures, 1055
- Occipital neuralgia, 1000
- Occupational therapy, for rheumatoid arthritis, 773
- Ocreotide  
 for acromegaly, 628  
 for dumping syndrome, 415  
 for TSH-secreting pituitary tumors, 629  
 for variceal hemorrhage, 461
- Odynophagia, 397, 401
- Ofatumumab, 590t
- Older adults  
 clinical care of, 1104  
 cognition in, 1108  
 comorbid conditions in, 1104-1106  
 continence in, 1109-1111  
 function and, 1104-1106  
 hearing in, 1109  
 life expectancy and, 1104-1106, 1106f  
 mobility in, 1109, 1110t  
 mood in, 1108-1109  
 nutrition in, 1111  
 vision in, 1109  
 geriatric care for, 1114  
 high-risk circumstances for, 1112  
 care transitions, 1112  
 hospitalized patient and, 1112  
 presentation of disease in, 1106-1107, 1107t  
 social and legal issues of, 1111-1112